Anemia is a common complication for patients who are undergoing chemotherapy, and one that has implications for patients’ quality of life, especially with respect to fatigue. During the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, Jérôme Desrame, MD, reported on results of the CIROCO study, which assessed fatigue in patients with chemotherapy-induced anemia who were treated with biosimilar epoetin alfa.
Anemia is a common complication for patients who are undergoing chemotherapy, and one that has implications for patients’ quality of life, especially with respect to fatigue. During the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, Jérôme Desrame, MD, reported on results of the CIROCO study, which assessed fatigue in patients with chemotherapy-induced anemia who were treated with biosimilar epoetin alfa.
The CIROCO study, funded by Sandoz, is a noninterventional, prospective, multicenter study of 538 adult patients who had 2 or more planned cycles of chemotherapy. The patients all had chemotherapy-induced anemia, and were receiving Sandoz’s biosimilar epoetin alfa (approved in the European Union under the brand names Epoetin Alfa Hexal, Abseamed, and Binocrit). Data were collected at inclusion, after a 2- to 3-month follow-up period, and after 4 to 6 cycles of chemotherapy.
Patients and their physicians separately assessed fatigue using a visual analogue scale (VAS) on a scale of 0 to 10; additionally, patients assessed their quality of life using the European Organization for the Research and Treatment of Cancer core quality of life questionnaire (EORTC QLQ C30).
Desrame and colleagues reported data for the subgroup of 434 patients with solid tumors. At baseline, mean hemoglobin was 9.7 (±0.8) g/dL. The mean increase in hemoglobin was 1.2 (±1.4) g/dL at 2 to 3 months of followup, and 0.4 (±1.5) g/dL after 4 to 6 cycles of chemotherapy.
In the safety population of 464 patients, 32.5% had adverse events (AEs) and 13.8% had serious AEs. However, only 3% of patients had AEs that were considered related to the study treatment.
In the full-analysis set population, between the 2- to 3-month follow-up measurement and the 4- to 6-cycle of chemotherapy measurement, the mean change in fatigue VAS score as reported by the patients was 5.2% (±92.6). The mean change in EORTC QLQ C30 score was 29.9 % (±98.0). Using the fatigue VAS, the physician assessment of fatigue was consistent with patient perceptions at all measurement timepoints.
The researchers concluded that biosimilar epoetin alfa was effective in treating these patients’ anemia, with improvements demonstrated in both hemoglobin levels and quality of life measurements.
Reference
Desrame J, et al. Correlation between fatigue evaluated with a visual analog scale (VAS) and quality of life (QoL) in cancer patients treated with biosimilar epoetin alfa for chemotherapy-induced anemia (CIA): the CIROCO study. Presented at the European Society for Medical Oncology (ESMO) 2018 Congress, October 19-23, 2018; Munich, Germany. Abstract 1790P. https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/show/session/258.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Promising Results for Ustekinumab, Adalimumab Biosimilars Presented at AAD
March 18th 2025Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved interchangeable with reference adalimumab, according to posters at the American Academy of Dermatology (AAD) annual meeting.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.